GlassScriptPhysician profile
Sharon A Johnson
NPI 1104951409
$1,375.80
in general payments reported to CMS, 2019-2025
19 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $487 · 2023: $256 · 2024: $236 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $290.70 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $242.34 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $171.80 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $115.59 | 2023-2025 | |
| Amgen INC. | $105.37 | 2024-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $90.73 | 2021-2023 | |
| Novo Nordisk INC | $84.28 | 2021-2022 | |
| Astellas Pharma US INC | $62.56 | 2021-2022 | |
| Philips North America LLC | $31.40 | 2024-2025 | (Ck7) Extended Holter, Holter |
| Horizon Therapeutics Plc | $23.47 | 2022 | |
| Axsome Therapeutics, INC. | $23.38 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $20.84 | 2023 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $17.52 | 2025 | Voquezna |
| Pfizer INC. | $17.18 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $16.94 | 2024 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $16.80 | 2022 | |
| Abbott Laboratories | $16.50 | 2025 | Id Now Instrument |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.22 | 2021 | |
| Phadia US INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.